article thumbnail

Prescribing Red Flags and Suspicious Controlled Substance Orders: Current Cautionary Tales

FDA Law Blog: Biosimilars

The order also enjoins the pharmacist-owner from serving as a PIC at any other pharmacy for seven years. Pharmacists and pharmacy management should pay heed to these prescribing red flags, resolve them when they appear and document their resolution. Consent Agreement and Final Judgment ¶ 17.

article thumbnail

Pharmacy Star Ratings Changes Coming in 2023

Digital Pharmacist

Health plans may act immediately to improve patient data collection and documentation related to these discrepancies by considering the following: Community collaboration: Health plans should consider collaborating with community outreach programs and enhancing incentives to promote community cooperation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What's the Next Billion Dollar Pharmacy Startup going to be?

The Digital Apothecary

Integrated Pharmacist EHR Systems - Most pharmacies use a 'Pharmacy Management System' to monitor drug inventory and verification and dispensing of medications, and not the clinical side of things. Last year I saw a fascinating article by and Watanabe and colleagues about how much medication-related issues impact the US.

article thumbnail

10 Opportunities to Leverage for Career Advancement

Amber

Courtney Manasco, RPH, is a Pharmacy Manager at Amber Specialty Pharmacy. Medical Transcriptionist Transcribing medical documents is work you can do from anywhere at hours convenient for you. This role helps you master the ability to hear medical jargon and then efficiently process what you hear into documents.

article thumbnail

FDA’s Proposal to Remove Oral Phenylephrine from the OTC Monograph Isn’t a Surprise but What is Left “Over-the-Counter”?

FDA Law Blog: Biosimilars

Along with the proposed order, FDA issued as a supporting document the “ Scientific Review Supporting Proposed Administrative Order ” in which it describes the scientific data on the efficacy, pharmacology, and safety of oral PE underlying its determination to issue the proposed order.